Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.57 USD
Change Today -0.17 / -3.59%
Volume 77.4K
CDXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 11:41 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Open
$4.70
Previous Close
$4.74
Day High
$4.75
Day Low
$4.46
52 Week High
04/15/15 - $5.65
52 Week Low
05/23/14 - $1.34
Market Cap
181.0M
Average Volume 10 Days
301.7K
EPS TTM
$-0.47
Shares Outstanding
39.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services and enzyme optimization services; and supplies enzymes, pharmaceutical intermediates, and active pharmaceutical ingredients. In addition, the company develops biocatalysts for use in the fine chemicals market, including food, animal feed, agricultural chemicals, and flavors and fragrances. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

91 Employees
Last Reported Date: 03/6/15
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $334.8K
Compensation as of Fiscal Year 2013.

codexis inc (CDXS) Key Developments

Codexis, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Codexis, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $14,191,000 against $9,525,000 a year ago. Income from operations was $450,000 against loss of $9,851,000 a year ago. Income before income taxes was $403,000 against loss of $9,858,000 a year ago. Net income was $345,000 or $0.01 basic and diluted per share against loss of $9,813,000 or $0.26 basic and diluted per share a year ago. Non-GAAP net income was $2,811,000 or $0.07 basic and diluted per share against loss of $4,721,000 or $0.12 basic and diluted per share a year ago. For the year, the company reported total revenues of $35,307,000 against $31,922,000 a year ago. Loss from operations was $19,111,000 against $41,146,000 a year ago. Loss before income taxes was $19,327,000 against $41,390,000 a year ago. Net loss was $19,071,000 or $0.50 basic and diluted per share against $41,303,000 or $1.08 basic and diluted per share a year ago. Non-GAAP net loss was $5,798,000 or $0.15 basic and diluted per share against $25,014,000 or $0.65 basic and diluted per share a year ago. The company is introducing financial guidance for 2015, as follows: total revenues of $39 million to $42 million, representing a 10% to 19% increase over 2014. This revenue guidance assumes recognizing a $6.5 million milestone related to the company's non-exclusive licensing agreement with GSK expected towards the end of 2015 and continued gross margins in the range of 70% to 75%.

Codexis, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Codexis, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 03, 2015

Codexis, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Codexis, Inc., Q4 2014 Earnings Call, Mar 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $4.57 USD -0.17

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $41.79 USD +0.31
Koninklijke DSM NV €52.66 EUR +0.88
Novozymes A/S kr335.00 DKK +3.90
Takasago International Corp ¥551.00 JPY +12.00
View Industry Companies
 

Industry Analysis

CDXS

Industry Average

Valuation CDXS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit www.codexis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.